As of Friday close, PTC Therapeutics Inc.’s (NASDAQ:PTCT) stock was down -$0.58, moving down -1.45 percent to $39.42. The average number of shares traded per day over the past five days has been 461,120 shares. 2 times new highs have been achieved over the past 5 days, with a -$2.26 fall in that time frame. In the last twenty days, the average volume was 661,690, while in the previous 50 days, it was 696,696.
Since last month, PTCT stock rose 0.69%. Shares of the company fell to $37.57 on 08/08/23, the lowest level in the past month. A 52-week high of $59.84 was reached on 05/22/23 after having rallying from a 52-week low of $33.25. Since the beginning of this year, PTCT’s stock price has risen by 3.27% or $1.25, and marked a new high 22 times. However, the stock has declined by -34.12% since its 52-week high.
PTCT stock investors should be aware that PTC Therapeutics Inc. (PTCT) stock had its last reported insider trading activity 73 days ago on Jun 07. SCHMERTZLER MICHAEL, the Director of the company, disposed of 1,000 shares for $44.86 on Jun 07. It resulted in a $44,860 divestment by the insider. Reeve Emma sold 2,652 shares at an average price of $59.53 on May 23. The insider now owns 7,200 shares following the transaction. On May 22, Director Reeve Emma sold 7,116 shares at $59.53 apiece. The transaction was valued at $423,630.
Financial Health
In the three months ended June 29, PTC Therapeutics Inc.’s quick ratio stood at 1.20, while its current ratio was 1.20, showing that the company is able to pay off its debt. On the profitability front, the trailing twelve-month gross margin is 93.70% percent. In the year ended June 29, EBITDA margin amounted to -43.10%, whereas operating margins totaled -72.80%. Based on annual data, PTCT earned $654.12 million in gross profit and brought in $698.8 million in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -41.70%. Return on equity (ROE) for the past 12 months was 153.50%.
In PTC Therapeutics Inc.’s quarter-end financial report for June 29, it reported total debt of $572.64 million against cash and short-term investments of $129.55 million. According to the earnings report, the company had a lower net income in the recent quarter than it did in the previous quarter. PTCT’s revenue rose 22.58% to $220.38 million during the quarter, while net income inched up to $213.81 million. While analysts expected PTC Therapeutics Inc. to report -$1.71 quarterly earnings, the actual figure was -$2.66 per share, beating the consensus estimate by -55.60%. During the quarter, the company generated $59.82 million in EBITDA. The liabilities of PTC Therapeutics Inc. were 1.92 billion at the end of its most recent quarter ended June 29, and its total debt was $1.47 billion. The value of shareholders’ equity is $75.34 million.
Technical Picture
This quick technical analysis looks at PTC Therapeutics Inc.’s (PTCT) price momentum. With a historical volatility rate of 28.30%, the RSI 9-day stood at 42.89% on 18 August.
With respect to its five-day moving average, the current PTC Therapeutics Inc. price is down by -5.42% percent or -$2.26. At present, PTCT shares trade -0.25% below its 20-day simple moving average and -13.85% percent below its 100-day simple moving average. However, the stock is currently trading approximately -9.55% below its SMA50 and +4.23% above its SMA200.
Stochastic coefficient K was 51.64% and Stochastic coefficient D was 64.50%, while ATR was 1.37. Given the Stochastic reading of 40.48% for the 14-day period, the RSI (14) reading has been calculated as 44.64%. As of today, the MACD Oscillator reading stands at -0.50, while the 14-day reading stands at -0.19.
Analyst Ratings
SVB Securities launched its rating on PTC Therapeutics Inc. (NASDAQ: PTCT) to a Market perform in a note to investors on March 17, 2023. PTC Therapeutics Inc. (PTCT) has been rated Overweight by analysts. According to 1 brokerage firm, PTCT is a sell, and 7 firms recommend it is a Hold. There are 1 analyst who say the stock is underweight. A total of 1 analyst rate PTC Therapeutics Inc. stock as buy, with 6 recommending it as overweight.
With a median target price of $49.00, the current consensus forecast for the stock is $35.00 – $73.00. Based on these forecasts, analysts predict PTC Therapeutics Inc. (PTCT) will achieve an average price target of $52.13.
